NSE filing, NSE: MARKSANS. Summary written from the filing by ALFA Finder's alert engine.
Marksans Pharma Ltd: key numbers
- Share price
- ₹326.75
- Market cap
- ₹14,807 Cr
- Revenue (annual)
- ₹2,951 Cr
- Net profit (annual)
- ₹417.9 Cr
- P/E (TTM)
- 28.6×Sector 41.3×
- Promoter holding
- 43.87%+0.00% QoQ
- FII holding
- 19.06%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Marksans Pharma Ltd
All →Marksans Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue ₹940cr (+30.5% YoY), EBITDA ₹214cr at 22.8% margin (+274bps), PAT ₹143.5cr (+44.8%). H1 PAT ₹303cr; net cash ₹1,095cr; Europe front-end being built.
Marksans Pharma Q2 FY27 Results: Net Profit ₹143.5 Cr, Up 44.8% YoY
Marksans Pharma Ltd reported revenue from operations of ₹940.2 Cr (+30.5% YoY) and net profit of ₹143.5 Cr (+44.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹143.5 Cr · +44.8% YoY
Marksans Pharma Board Meeting Date
Marksans Pharma scheduled its Board meeting for November 4, 2026, to approve Q1/H1 unaudited results. No material decision has been taken yet.
Marksans Pharma Other Announcement
Periodic quarterly shareholding pattern filing for Marksans Pharma Ltd. This document provides the latest breakdown of shareholder categories as mandated by SEBI.
Marksans Pharma Promoter Selling (Off-Market)
Director Sandra Saldanha gifted 2,28,273 shares of Marksans Pharma Ltd to her daughters in an off-market transaction. This internal transfer reallocates promoter-group equity holdings.
Marksans Pharma Other Announcement
Marksans Pharma intimated shareholders about SEBI's extended special window (Feb 2026–Feb 2027) for re-lodgement of pre-April-2019 physical share transfer deeds. No new business, capital, or operational event is disclosed.
Other results update announcements
All →Steel Exchange India Results Update
Steel Exchange India Ltd reported a nine-fold surge in Q2 FY27 PAT to ₹18 Crore. Revenue rose 46% to ₹343 Crore alongside a ₹102 Crore debt reduction.
- quarterly production
- 69617.42 MT
Alembic Pharmaceuticals Results Update
Alembic Pharmaceuticals reported Q2 FY27 revenue growth of 36% to ₹2,603 Crore. Net profit surged 81% to ₹335 Crore, driven by exceptional US business performance.
- Value
- ₹2,603 Cr
SJS Enterprises Results Update
S.J.S. Enterprises reported record quarterly revenue of Rs. 282.73 Crore, up 16.9% YoY. Net profit for Q2FY27 rose 34.8% YoY to Rs. 58.33 Crore.
- Value
- ₹282.7 Cr
Meghmani Organics Results Update
MOL reported Q2 FY27 revenue of ₹658.2 crore, up 18% YoY, with net profit of ₹45.3 crore. EBITDA margin eased to 10.8% on elevated input costs.
GPT Infraprojects Results Update
GPT Infraprojects reported Q2 FY27 revenue of ₹291.4 crore and PAT of ₹18.3 crore. Order inflow was ₹1,491 crore; interim dividend of ₹1 declared.
- Order book
- ₹5,373 Cr
Indo Count Industries Results Update
Indo Count reported record Q2 FY27 income of ₹1,699 Cr and PAT of ₹132 Cr. H1 EBITDA grew 73% YoY to ₹420 Cr.